



Polycythemia Vera

CLINICAL RESISTANCE/INTOLERANCE TO HYDROXYUREA IN POLYCYTHEMIA VERA


Alessandro Maria **Vannucchi**, Paola **Guglielmelli**, Fabrizio **Pane**,
Francesco **Passamonti**, Valerio **De Stefano**, Massimo **Breccia**, Elisabetta **Abruzzese**
Francesca **Palandri**, Tiziano **Barbui**

Definition of Clinical Resistance/Intolerance to Hydroxyurea in Polycythemia Vera

RESISTANCE	INTOLERANCE	Hydroxyurea (HU)
<ul style="list-style-type: none"> Need of phlebotomy to maintain Hct <45% 		
<ul style="list-style-type: none"> Platelets (PLT) >400x10⁹/L <i>and</i> WBC >10x10⁹/L 		After 3 months of at least 2 g/day HU
<ul style="list-style-type: none"> Spleen reduction by <50% <i>or</i> No complete relief of spleen-related symptoms 		
	<ul style="list-style-type: none"> ANC <10⁹/L <i>or</i> PLT <100x10⁹/L <i>or</i> Hb <100g/L 	At the lowest dose required to achieve complete or partial hematologic response (ELN criteria)
	<ul style="list-style-type: none"> <u>Leg ulcers</u> <i>or</i> Other unacceptable HU-related toxicities* 	At any dose of HU

*Mucocutaneous, gastrointestinal, pneumonitis, fever





Il presente documento è il prodotto finale del progetto *Clinical Assessment of resistance and Intolerance to Hydroxyurea as Criteria for Second-line Treatment in patients with Polycythemia Vera*, condotto nel corso del 2023 e 2024 dal Working Party GIMEMA sulle Neoplasie Mieloproliferative Croniche.

EXPERT PANEL

Alessandro Maria **Vannucchi** (coordinatore)

Paola **Guglielmelli** (referente di progetto)

Fabrizio **Pane**

Francesco **Passamonti**

Valerio **De Stefano**

Massimo **Breccia**

Elisabetta **Abruzzese**

Francesca **Palandri**

Tiziano **Barbui**

Questo progetto è stato realizzato con il supporto non condizionante di **AOP Health**.

